Dogwood Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $49.6M
- Price
- $1.46
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.10%
- Volume
- 10.4K
About
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Quick stats
Shares outstanding34.0M
Computed float9.3M
Float / shares27.4%
Cash runway (months)3.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001818844
Websitehttps://www.dwtx.com
AI Summary
AI-generated1/14
minorneutralother
Dogwood to Participate in the 2026 Maxim Growth Summit
Dogwood Therapeutics announced management will participate in the 2026 Maxim Growth Summit on October 12-14 in New York.
CEO and Chairman Greg Duncan will hold one-on-one meetings with institutional investors and Maxim research analysts; portions of the event will be streamed online.
The company reiterated that its Halneuron Phase 2b trial completed enrollment with topline data expected in November 2026.